Recent News
A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific ratesRead Article
EULAR26: Vasculitis updates: Glucorticoid use in AAV and GCA
EurekAlert!
EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids.1 The introduction of biologics such as rituximab as maintenance in AAV has reduced the rate of flares,3-6 but it is not clear whether concomitant low-dose glucocorticoids during the same period provides an
Read Article
Insights into Treating Lupus - A Rheum Survey
RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed the survey.
Read Article
ICYMI: VEXAS Syndrome - A Review
Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.
Read Article
EULAR26: GLP-1 Agonist Use in the RISE Registry
EurekAlert!
At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD).
Read Article
RT @minidey #OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous & MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026
Dr. John Cush @RheumNow ( View Tweet)
RT @aurelierheumo Failure to achieve early remission RA asso w/ non-inflammatory pain
NORD-STAR 526 early RA pts)
no remission at 24 wks increased risk of 48wk
• unacceptable pain (OR ~6)
• refractory pain (OR ~6)
• fibromyalgic RA (OR ~16)
Signal strongest w/ very early
Dr. John Cush @RheumNow ( View Tweet)
EULAR26: Reports on Systemic Sclerosis
https://t.co/knZZlMYlen https://t.co/0wul0yaw4m
Dr. John Cush @RheumNow ( View Tweet)
Generic Tofacitinib (6.26.2026)
Dr. Jack Cush reviews the news and journal articles from https://t.co/V10S4oVFsv. Updates on tofacitinib, CAR-T therapy and AI.
https://t.co/DNWh7taaN6 https://t.co/4r5fuooqWn
Dr. John Cush @RheumNow ( View Tweet)
EULAR26: Updates in SLE and APS
Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants.
https://t.co/DP7gPvlGhU https://t.co/imN6Xb7QGT
Dr. John Cush @RheumNow ( View Tweet)
ICYMI: Glucocorticoid Injections in Knee Osteoarthritis
A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (compared to placebo).
Read Article
ICYMI: EGPA Review
A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.
Read Article
Spotlight on Comorbidities from EULAR 2026
EurekAlert!
Systemic autoimmune diseases are associated with increased cardiovascular morbidity and mortality – possibly through autonomic imbalance, myocardial inflammation, or fibrotic infiltration of the conduction system. A team in Colombia have been looking into the risk of cardiac arrhythmias and conduction disorders in adults with systemic autoimmune diseases compared with the general population – with the aim of
Read Article
Is it all over for avacopan? #Vasculitis
https://t.co/1sFUidC6Cw
Rheuma Doc @LastManStand85 ( View Tweet)
RT @jiharheum : ETA+MTX vs triple therapy after MTX failure in #RA: machine learning-emulated RACAT trial (n=3,472 VA pts) confirms ETA+MTX modestly better overall. But smoking matters: benefit disappears in current smokers. Precision medicine from RWD. #EULAR2026 POS0255
Dr. John Cush @RheumNow ( View Tweet)
RT @drminidey
#OP0208 #EULAR2026: phase 3 COURAGE-RA trial showed strong efficacy for selective JAK1 inhibitor zemprocitinib in D2T RA after bDMARD failure. Responses were rapid (from week 2), sustained through week 24 and achieved with a reassuring safety profile.
Dr. John Cush @RheumNow ( View Tweet)
Which is NOT a key feature of inflammatory back pain: relief with activity; morning stiffness; age under 40 years; unilateral pain? Test your knowledge in this week's RheumIQ quiz at https://t.co/z8mLbcgE5D. https://t.co/tOdPfEBJa4
Dr. John Cush @RheumNow ( View Tweet)
Obexelimab in IgG4-Related Disease: INDIGO Trial
Dr. Henrique Dalmolin reports on abstract OP018 from EULAR 2026.
https://t.co/Wid9ZzESae https://t.co/Qo4y8ebkOn
Dr. John Cush @RheumNow ( View Tweet)
2026 Guidelines for the Treatment of Axial Spondyloarthritis
New guidelines offer clinicians and patients clearer directions on diagnostic workup, treatment selection, and long-term disease management, while emphasizing shared decision-making due to ongoing evidence gap. https://t.co/SUFnOMAUw8
Dr. John Cush @RheumNow ( View Tweet)
Self-Directed Cognitive Behavioral Therapy for Chronic Pain
Is self-directed cognitive behavioral therapy (CBT) when augmented with asynchronous, personalized feedback for chronic pain (CBT-CP) superior to clinician-delivered CBT-CP?
https://t.co/P2DDvCiLNL https://t.co/hyAArEG6V1
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
Generic Tofacitinib (6.26.2026)
DERM on RheumNow (June 2026)-
Do You Zoster Vaccinate? (6.19.2026)
RheumNow EULAR 2026 Rheumatology Round Up
Therapeutic Updates
Fundamentals of CAR T Cell Therapy and Its Investigational Use in Autoimmune Diseases
Sponsored By Bristol Myers Squibb
Therapeutic Update
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
